Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA)

What Was Tested

Researchers studied Semaglutide in this randomized controlled trial publication.

Non-invasive test (NIT)-based assessment of eligibility and treatment response with semaglutide is needed to inform clinical practice guidance.

Therefore, utilising a randomised, placebo-controlled study design, the researchers evaluated the utility of NITs to assess eligibility and treatment response in patients with suspected at-risk MASH randomised to semaglutide versus placebo.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The primary outcome was change in the FAST score at end of treatment from baseline.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Some participants received a placebo instead of Semaglutide, giving a reference point.

More than one site took part, so the participants came from several places.

Other endpoints included changes in body weight, MRI-PDFF, ALT and HbA1c.

What Was Measured

PubMed files the paper under topics including Semaglutide, Glucagon-Like Peptides, Hypoglycemic Agents, Diabetes Mellitus, Type 2, Glycated Hemoglobin and Non-alcoholic Fatty Liver Disease.

The authors tagged it with the keywords VCTE, glucagon‐like peptide 1 receptor agonists, metabolic dysfunction, noninvasive tests and steatotic liver disease.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Alimentary pharmacology & therapeutics), a journal based in England.

More context: the Semaglutide compound page, all human trials.